Is BLCO or SOLV more profitable?

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -4.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -4.21% 3.60% 1.69% Solventum 17.33% 23.51% 7.63%

Which has stronger valuation and earnings, SNN or BLCO?

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.04 $625M N/A N/A Bausch + Lomb $5.10B 1.07 -$360M -$0.62 N/A

Is PEN or BLCO more profitable?

Penumbra has a net margin of 11.76% compared to Bausch + Lomb's net margin of -4.21%. Penumbra's return on equity of 10.87% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 11.76% 10.87% 8.45% Bausch + Lomb -4.21% 3.60% 1.69%

Which has preferable earnings & valuation, BLCO or GKOS?

Glaukos has lower revenue, but higher earnings than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch + Lomb $5.10B 1.07 -$360M -$0.62 N/A Glaukos $507.44M 15.64 -$187.69M -$3.28 N/A

Is BLCO or GKOS more profitable?

Bausch + Lomb has a net margin of -4.21% compared to Glaukos' net margin of -34.34%. Bausch + Lomb's return on equity of 3.60% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -4.21% 3.60% 1.69% Glaukos -34.34% -6.92% -5.25%

Bausch + Lomb (BLCO) Competitors

$15.25 +0.32 (+2.14%)

Closing price 03:58 PM Eastern

Extended Trading

$15.10 -0.15 (-1.02%)

As of 06:49 PM Eastern

Compare

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy Bausch + Lomb stock or one of its competitors? MarketBeat compares Bausch + Lomb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch + Lomb include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does Bausch + Lomb compare to Zimmer Biomet?

Bausch + Lomb (NYSE:BLCO) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Bausch + Lomb has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Zimmer Biomet has a net margin of 9.05% compared to Bausch + Lomb's net margin of -4.21%. Zimmer Biomet's return on equity of 13.24% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Zimmer Biomet	9.05%	13.24%	7.28%

In the previous week, Zimmer Biomet had 8 more articles in the media than Bausch + Lomb. MarketBeat recorded 8 mentions for Zimmer Biomet and 0 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.19 beat Bausch + Lomb's score of 0.98 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch + Lomb	Positive
Zimmer Biomet	Positive

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bausch + Lomb presently has a consensus price target of $17.92, suggesting a potential upside of 17.49%. Zimmer Biomet has a consensus price target of $102.70, suggesting a potential upside of 17.18%. Given Bausch + Lomb's higher possible upside, research analysts plainly believe Bausch + Lomb is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A
Zimmer Biomet	$8.23B	2.06	$705.20M	$3.85	22.76

Summary

Zimmer Biomet beats Bausch + Lomb on 13 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Solventum?

Bausch + Lomb (NYSE:BLCO) and Solventum (NYSE:SOLV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

11.1% of Bausch + Lomb shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bausch + Lomb has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Solventum has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A
Solventum	$8.33B	1.54	$1.56B	$8.16	9.09

Bausch + Lomb presently has a consensus target price of $17.92, suggesting a potential upside of 17.49%. Solventum has a consensus target price of $84.25, suggesting a potential upside of 13.64%. Given Bausch + Lomb's higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -4.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Solventum	17.33%	23.51%	7.63%

In the previous week, Solventum had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 3 mentions for Solventum and 0 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.98 beat Solventum's score of 0.25 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Overall Sentiment
Bausch + Lomb	Positive
Solventum	Neutral

Summary

Solventum beats Bausch + Lomb on 11 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Smith & Nephew SNATS currently has a consensus target price of $30.93, suggesting a potential upside of 4.41%. Bausch + Lomb has a consensus target price of $17.92, suggesting a potential upside of 17.49%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Smith & Nephew SNATS has a net margin of 0.00% compared to Bausch + Lomb's net margin of -4.21%. Bausch + Lomb's return on equity of 3.60% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Bausch + Lomb	-4.21%	3.60%	1.69%

In the previous week, Bausch + Lomb's average media sentiment score of 0.98 beat Smith & Nephew SNATS's score of 0.00 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Overall Sentiment
Smith & Nephew SNATS	Neutral
Bausch + Lomb	Positive

Smith & Nephew SNATS has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.04	$625M	N/A	N/A
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A

Summary

Bausch + Lomb beats Smith & Nephew SNATS on 8 of the 13 factors compared between the two stocks.

How does Bausch + Lomb compare to Penumbra?

Penumbra (NYSE:PEN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Penumbra currently has a consensus price target of $361.33, indicating a potential upside of 13.60%. Bausch + Lomb has a consensus price target of $17.92, indicating a potential upside of 17.49%. Given Bausch + Lomb's stronger consensus rating and higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

88.9% of Penumbra shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Penumbra has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Penumbra has a net margin of 11.76% compared to Bausch + Lomb's net margin of -4.21%. Penumbra's return on equity of 10.87% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Bausch + Lomb	-4.21%	3.60%	1.69%

In the previous week, Penumbra had 2 more articles in the media than Bausch + Lomb. MarketBeat recorded 2 mentions for Penumbra and 0 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.98 beat Penumbra's score of 0.68 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Overall Sentiment
Penumbra	Positive
Bausch + Lomb	Positive

Penumbra has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.91	$177.69M	$4.34	73.29
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A

Summary

Penumbra beats Bausch + Lomb on 11 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Glaukos?

Bausch + Lomb (NYSE:BLCO) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 5.9% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bausch + Lomb presently has a consensus target price of $17.92, suggesting a potential upside of 17.49%. Glaukos has a consensus target price of $149.17, suggesting a potential upside of 10.42%. Given Bausch + Lomb's higher probable upside, equities analysts plainly believe Bausch + Lomb is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

In the previous week, Glaukos had 6 more articles in the media than Bausch + Lomb. MarketBeat recorded 6 mentions for Glaukos and 0 mentions for Bausch + Lomb. Glaukos' average media sentiment score of 0.99 beat Bausch + Lomb's score of 0.98 indicating that Glaukos is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch + Lomb	Positive
Glaukos	Positive

Bausch + Lomb has a net margin of -4.21% compared to Glaukos' net margin of -34.34%. Bausch + Lomb's return on equity of 3.60% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Glaukos	-34.34%	-6.92%	-5.25%

Glaukos has lower revenue, but higher earnings than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A
Glaukos	$507.44M	15.64	-$187.69M	-$3.28	N/A

Bausch + Lomb has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Summary

Glaukos beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLCO vs. The Competition

Export

Metric	Bausch + Lomb	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$5.33B	$8.67B	$6.46B	$23.15B
Dividend Yield	N/A	1.73%	2.68%	4.06%
P/E Ratio	22.97	23.42	24.71	31.08
Price / Sales	1.07	16.77	492.47	108.25
Price / Cash	8.95	13.96	27.92	18.65
Price / Book	0.83	6.21	10.82	4.65
Net Income	-$360M	$174.80M	$3.56B	$1.07B
7 Day Performance	1.78%	2.03%	1.67%	-1.04%
1 Month Performance	-4.39%	1.54%	0.43%	0.18%
1 Year Performance	27.03%	10.30%	32.84%	24.25%

Bausch + Lomb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLCO Bausch + Lomb	3.5103 of 5 stars	$15.25 +2.1%	$17.92 +17.5%	+27.4%	$5.33B	$5.10B	22.97	13,000
ZBH Zimmer Biomet	4.7332 of 5 stars	$88.54 +1.6%	$102.70 +16.0%	-4.3%	$17.13B	$8.41B	23.00	17,000	Positive News
SOLV Solventum	3.4852 of 5 stars	$78.85 -0.5%	$84.25 +6.8%	-0.1%	$13.66B	$8.26B	9.66	20,000
SNN Smith & Nephew SNATS	2.0944 of 5 stars	$30.52 -0.5%	$30.93 +1.3%	+2.0%	$13.00B	$6.16B	N/A	16,988
PEN Penumbra	2.5313 of 5 stars	$318.63 +0.1%	$361.33 +13.4%	+23.3%	$12.54B	$1.40B	73.42	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BLCO) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Summary

How does Bausch + Lomb compare to Solventum?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Summary

How does Bausch + Lomb compare to Penumbra?

Summary

How does Bausch + Lomb compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Which has more volatility & risk, BLCO or ZBH?

Is BLCO or ZBH more profitable?

Does the media refer more to BLCO or ZBH?

Do institutionals and insiders have more ownership in BLCO or ZBH?

Do analysts rate BLCO or ZBH?

Which has stronger valuation and earnings, BLCO or ZBH?

Summary

How does Bausch + Lomb compare to Solventum?

Do institutionals and insiders hold more shares of BLCO or SOLV?

Which has more volatility & risk, BLCO or SOLV?

Which has better valuation and earnings, BLCO or SOLV?

Do analysts recommend BLCO or SOLV?

Is BLCO or SOLV more profitable?

Does the media favor BLCO or SOLV?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Do analysts recommend SNN or BLCO?

Do insiders & institutionals hold more shares of SNN or BLCO?

Is SNN or BLCO more profitable?

Does the media prefer SNN or BLCO?

Which has more risk and volatility, SNN or BLCO?

Which has stronger valuation and earnings, SNN or BLCO?

Summary

How does Bausch + Lomb compare to Penumbra?

Do analysts prefer PEN or BLCO?

Do insiders and institutionals have more ownership in PEN or BLCO?

Which has more volatility and risk, PEN or BLCO?

Is PEN or BLCO more profitable?

Does the media refer more to PEN or BLCO?

Which has preferable earnings & valuation, PEN or BLCO?

Summary

How does Bausch + Lomb compare to Glaukos?

Do institutionals & insiders hold more shares of BLCO or GKOS?

Do analysts recommend BLCO or GKOS?

Does the media favor BLCO or GKOS?

Is BLCO or GKOS more profitable?

Which has preferable earnings & valuation, BLCO or GKOS?

Which has more risk and volatility, BLCO or GKOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools